BACKGROUND The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic therapy (warfarin) for
patients and w6,000 PY of follow-up, we provide the most comprehensive assessment to date of the efficacy of Watchman LAAC for stroke prevention.
METHODS
Local institutional review board approval was obtained for each dataset. All clinical trials were registered on ClinicalTrials.gov (1, 3, 4) . The specific Watchman device was identical throughout; a selfexpanding nitinol framed structure positioned at LAA ostium with diameter ranges from 20 to 33 mm and fixation barbs to prevent embolization (9) . Implant protocols were identical. As previously described (1, 4, 9) , after implantation, patients were treated with warfarin with an international normal- plete LAAC or if residual peridevice flow was <5 mm in width, warfarin was discontinued and the patient was treated with clopidogrel 75 mg and aspirin 81 to 325 mg until 6 months following implantation, at which time clopidogrel was discontinued and 325 mg of aspirin was used indefinitely. In the control (warfarin) limb, INR was monitored every 2 weeks to achieve an INR of 2 to 3. All patients had follow-up visits at 45 days, and at 6, 9, and 12 months, and then twice yearly.
All 4 datasets included a primary efficacy composite of all cause stroke (both hemorrhagic and ischemic), systemic embolization, and CV death. Any death of unknown origin was included as CV. Safety endpoints varied slightly between the 2 randomized trials and included bleeding as well as all cause stroke (ischemic and hemorrhagic). To be a candidate for the device, all patients had to be able to take warfarin for 45 days following implantation.
Because of the identical efficacy endpoint definitions in both randomized trials, the data from both trials were pooled for this meta-analysis (1,4).
PROTECT AF STUDY. Eligibility criteria included $18 years of age with paroxysmal persistent or permanent AF with a CHADS 2 risk score $1. Exclusion criteria included absolute contraindications to warfarin, LAA thrombus, a patent foramen ovale with an atrial septal aneurysm and right to left shunt, mobile aortic atheroma, or symptomatic carotid disease. The primary composite safety endpoint included excessive bleeding or procedural-related complications (e.g., pericardial effusion requiring intervention, device embolization, or procedural-related stroke). A Bayesian statistical model (12) was used for noninferiority trial design, and pre-specified endpoint analysis of observed event rates after 600 follow-up PY and after each additional 150 PY, up to 1,500.
PREVAIL TRIAL. Selection criteria were modified to include higher risk patients: a CHADS 2 score $2 or a CHADS 2 score $1 with more than 1 of the following higher risk characteristics; female $75 years of age, baseline ejection fraction $30% but <35%, 65 to 74 years of age with either diabetes or coronary artery disease, and $65 years of age with heart failure. Exclusion criteria were similar to the PROTECT AF trial, except patients in whom clopidogrel therapy was indicated were excluded because of the potential confounding influence of this drug on efficacy outcome. DEFINITIONS. For all data sets, the CHADS 2 score (1,4) was used for patient entry. Because the CHA 2 DS 2 -VASc score has largely supplanted CHADS 2 (13) (14) (15) (16) , risk prediction was reported using both. Table 2) ; mean patient age ranged from 72.0 AE 8.9 years of age in the PROTECT AF trial to 75.3 AE 8.0 years of age in CAP2. The CHADS 2 score similarly ranged from 2.2 AE 1.2 to 2.7 AE 1.1 (p < 0.0001) as did the CHA 2 DS 2 -VASc score 3.5 AE 1.6 to 4.5 AE 1.3 (p < 0.0001). On the basis of these scores, the total predicted annualized risk for stroke, if untreated with anticoagulation, ranged from 5.7% to 7.6% annually.
The distribution of both CHADS 2 and CHA 2 DS 2 -VASc scores documented the majority of patients were high risk for stroke and all were eligible for warfarin ( Figures 1A and 1B) . Conversely, 90% of pa-endpoint of stroke, systemic embolism, and CV death. Values are mean AE SD or %.
CHF ¼ congestive heart failure; other abbreviations as in Table 1 . Holmes, Jr. et al. bleeding was similar between groups, when periprocedural bleeding was excluded, bleeding rates were significantly higher in patients treated with chronic warfarin; 6) device performance was consistent over the entire data set-both randomized clinical trials and registries, the latter of which are likely to more closely resemble real world experience.
The relationship between the increasing incidence of NVAF and consequent stroke is well described:
stroke rates are increased 4-to 5-fold, larger and more debilitating with hemorrhagic conversion, and higher recurrence rates (13, (17) (18) (19) (20) . In patients >80 years of age, AF is believed to be responsible for 15% to 30% of 
Stroke Prevention in Nonvalvular Atrial Fibrillation 1.55) (30) . These new agents have not become dominant in the field of stroke prevention for several reasons, including cost, lack of antidotes, need for twice daily dosing (with 2 of the agents), and side effects. In addition, by 2 years, 21% to 33% of patients discontinued the NOAC, and the major bleeding rate per year was 2 to 3.5%, both of which are similar to that reported for conventional warfarin (26) (27) (28) .
The LAA has been implicated as the source of emboli in w90% of patients with NVAF ( The combined data set of all PROTECT AF and PREVAIL Watchman patients versus chronic warfarin patients documented: 1) similarity in overall stroke or systemic embolism;
2) ischemic stroke slightly increased with Watchman but hemorrhagic stroke significantly decreased with warfarin; and 3) all-cause mortality and major nonprocedural bleeding both significantly improved with Watchman. CI ¼ confidence interval; CV ¼ cardiovascular;
HR ¼ hazard ratio; SE ¼ systemic embolism; other abbreviations as in Figure 1 . Another question not answered by these analyses is the relative effect of the device compared to currently approved NOACs. Currently, there are no data comparing LAAC to any of the NOACs. It must be remembered that even in the randomized NOAC trials, the 2-year drug discontinuation rates ranged between 21% and 33%, and for these patients, the protective effect of the drug would accordingly be lost (26) (27) (28) .
Though warfarin has been extensively studied and has well-characterized efficacy rates, it should be noted that the Watchman trials were randomized in a 2-to-1 fashion, thus resulting in a limited number of warfarin patients with whom to compare the device, and the majority of device patients in this analysis (62%) were registry patients.
CONCLUSIONS
In the setting of NVAF with increased stroke risk, systemic embolism, or CV death, patients who are 
